Skip to content

FLOWERS PHARMA

Active
Private limited companyfounded 201610 yrs activeRue Pasteur 39, 6032 Charleroi, BelgiumKBO/BCE: BE 0650.852.776
Summary

FLOWERS PHARMA has been active since 2016 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (-€72,346) and a net result of -€34,570. Equity is growing by ~5.4% per year across the filed fiscal years. Its solvency ranks better than 10% of 11293 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 1.2% (low).

Risk analysisWatch ReportCompare
FLOWERS PHARMAActiveChecked score 34/100
Risk analysis ReportCompare

Overview

What they do
Retail sale of pharmaceutical products
NACE 47730
1 site
How big
€516,128total assets 2025
Staff
3.2 FTE
Equity
-€72,346
Loss
-€34,570
Financially healthy?
34 Weak Checked score 2025
Bankruptcy chance 12 m
1.2%
Who decides
Accounts filed 24 d late0 of 2 deeds read
Why 34- Higher-failure-rate sector- Annual accounts: weaker financial profile- Higher-failure-rate region- Negative equityA punctual record breaksShow the evidence

Checked score

Score 2025
34 / 100
Weak
Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability10▼-57
Solvency11▼-7
Growth32▼-46
Track record100
Bankruptcy probability, 12 months
1.2% Low
0%0.5%1.5%4%10%≥ 25%
No credit on open account
Liquidity short (current ratio 0.72 against 0.82 in 2024; short-term debt: 114% and cash: 34.3% of total assets), and equity is negative.
Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Five signals. The signal on the left, the evidence on the right.
+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Retail trade (NACE 47)
about 45% more bankruptcies
← fewer bankruptcies more bankruptcies →
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2025
Solvency, return and age of the figures
Solvency
-14%
Return on assets
-6.7%
Age of the figures
9 mo
raises risk · Higher-failure-rate region
In this region companies fail more often than in the rest of the country.
KBO · registered office
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025
Equity per financial year
1819202122232425
2018 to 2025 · latest year -€72,346
neutral · A punctual record breaks
This company filed 8 consecutive financial years on time. The year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 24-08-2026, 24 days late. Weigh it accordingly: a break into the 1-to-90-day band measures 1.41% abnormal legal state, below the 1.66% market average. It is a change in behaviour, not evidence of elevated risk.
NBB · 10 filings
Deviation from the deadline
2025
24 d late
2024
5 d early
2023
13 d early
2022
39 d early
2021
56 d early
2020
39 d early
2019
55 d early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 26 days before the deadline; the sector median for financial year 2024 is on the deadline day, and 47% of the sector filed late.

Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 19 July (4 of the last 5 filed years within 36 days of that day).
Companies Code · seven months
Position in the running window
02-10-2026 today31-12-2026 close31-07-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage
  1. Annual accounts filedfiscal year 2025 · abbreviated…
  2. Annual accounts filedfiscal year 2024 · full…
  3. Annual accounts filedfiscal year 2023 · full…

Key points

  • Risk: Negative equityfiscal year 2025: debts exceed assets -€72,346 View
  • Risk: 3 loss-making years in a rowloss fiscal year 2025 -€34,570 View
  • Caution: Among the weakest 8% on equitysector median €247,818 · 11,303 companies -€72,346 View

By topic

Financials

Fiscal year
2025
Total assets
€516,128
Loss
-€34,570
Solvency
-14.0%
Total assets▼ 7.6%
Net result
20182025
Go to Financials

Timeline

Events
12
Since
2017
Next accounts
by 31-07-2027
  1. 24-08-2026Annual accounts filed
  2. 26-07-2025Annual accounts filed
  3. 18-07-2024Annual accounts filed
Go to Timeline

Company details

Sites
1
Legal form
Private limited company
Activity
Retail sale of pharmaceutical productsNACE 47730
Founded
30-03-2016
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Go further with this company

How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure